Haemonetics (HAE) Set to Announce Quarterly Earnings on Thursday

Haemonetics (NYSE:HAE) will be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect Haemonetics to post earnings of $1.09 per share for the quarter. Haemonetics has set its FY25 guidance at $4.45 to $4.75 EPS and its FY 2025 guidance at 4.450-4.750 EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). The company had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. Haemonetics’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.05 earnings per share. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Price Performance

Haemonetics stock opened at $73.53 on Tuesday. The firm has a market capitalization of $3.76 billion, a PE ratio of 32.97, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The firm has a 50-day moving average price of $75.40 and a 200-day moving average price of $82.67. Haemonetics has a 12-month low of $70.25 and a 12-month high of $97.97. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35.

Analyst Ratings Changes

HAE has been the subject of a number of research reports. CL King started coverage on Haemonetics in a report on Friday, September 13th. They issued a “buy” rating and a $116.00 price target for the company. Citigroup reduced their target price on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Bank of America began coverage on Haemonetics in a research note on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price objective for the company. JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 13th. Finally, Barrington Research restated an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a research report on Monday, September 23rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.14.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.